This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Arena Pharma: Slow Belviq Launch but No Matter for Bel-Phen Data Coming

SAN DIEGO ( TheStreet) -- A slow launch for the weight-loss pill Belviq was somewhat expected, so before getting into details of sales reported Thursday, let's first talk about the "new" new Arena Pharmaceuticals (ARNA - Get Report) bull thesis: Bel-Phen.

Arena and its partner Eisai announced plans to conduct a 12-week pilot study combining Belviq with phentermine, a currently approved weight-loss medicine. Details about the design of the study were not disclosed, although patient enrollment is expected to begin late this year or early in 2014, Arena said.

Given 12 weeks of treatment, a rough guess would be top-line results announced in the second half of 2014. This catalyst now becomes the bright and shiny object of hope for Arena supporters.

They believe Bel-Phen will be the next Fen-Phen weight-loss blockbuster therapy -- minus the pesky problem of melting heart valves, of course. Belviq (lorcaserin) is chemically similar to fenfluramine, except the former is not supposed to cause the serious heart defects which caused the latter to be yanked off the market.

Whether or not Bel-Phen will be found to be heart safe remains to be seen.

Arena shares are trading down just 1% to $6.88 Thursday morning, which I attribute to the announcement of the first Bel-Phen study and little surprise about the slow Belviq launch given close tracking of weekly prescription data.

Arena reported $1.3 million in Belviq net product sales in the second quarter, which is 31.5 percent of the $4.1 million in net product sales recorded by Eisai.

Belviq hit pharmacy shelves in the beginning of June, so we're only talking about a month of sales in the second quarter. Still, $4.1 million in net product sales is light, especially considering that number includes inventory stocking.

Belviq's reported net sales underwhelmed, in part, because Eisai is giving away tons of free samples. It's estimated that between 60-70 percent of all Belviq prescriptions filled are gratis.

Separately, Eisai reported $10 million in gross sales of Belviq, which means the gross-to-net discount was a whopping 60 percent.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.75 -1.10%
AAPL $93.39 -1.50%
FB $116.19 -0.46%
GOOG $691.59 0.08%
TSLA $241.50 -2.50%


Chart of I:DJI
DOW 17,677.25 -153.51 -0.86%
S&P 500 2,057.17 -18.64 -0.90%
NASDAQ 4,755.0480 -50.2430 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs